Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crinetics Pharmaceuticals, Inc. - Common Stock (NQ: CRNX )

53.60 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2
Open 53.60
Bid (Size) 21.44 (2)
Ask (Size) 57.88 (2)
Prev. Close 53.60
Today's Range 53.60 - 53.60
52wk Range 33.67 - 62.53
Shares Outstanding 54,026,103
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential
Neurocrine's Crenessity receives FDA approval as a groundbreaking adjunctive treatment for classic CAH, offering a novel approach to hormone regulation. 
Via Benzinga
Exposures Product Safety
Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
+51.46%
+51.46%
1 Month
-4.39%
-4.39%
3 Month
+6.31%
+6.31%
6 Month
+17.39%
+17.39%
1 Year
+48.44%
+48.44%

More News

Read More
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Earnings Scheduled For November 12, 2024
Via Benzinga
What Analysts Are Saying About Crinetics Pharmaceuticals Stock
Via Benzinga
A Closer Look at 11 Analyst Recommendations For Crinetics Pharmaceuticals
Via Benzinga
Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
CRNX Stock Earnings: Crinetics Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.